Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib + tislelizumab + paclitaxel liposome + nedaplatin as neoadjuvant therapy for esophageal squamous cell carcinoma
ChiCTR2100043836Phase 2Recruiting
- Sponsor
- The First Affiliated Hospital of Guangxi Medical University
- Start
- Apr 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib, tislelizumab, liposomal paclitaxel and nedaplatin in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by The First Affiliated Hospital of Guangxi Medical University. Primary endpoints: Objective response rate and Overall survival. Started Apr 2021; status: recruiting.
02
Drugs
anlotinibtislelizumabliposomal paclitaxelnedaplatin
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2100043836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100043836.